PDGFR expression in differential diagnosis between KIT‐negative gastrointestinal stromal tumours and other primary soft‐tissue tumours of the gastrointestinal tract

Aims : To investigate the value of platelet‐derived growth factor receptors (PDGFRs) by immunohistochemistry in discriminating KIT‐negative gastrointestinal stromal tumours (GISTs) from other soft‐tissue neoplasms of the digestive tract.

[1]  Kam-cheong Lee,et al.  A malignant gastrointestinal stromal tumor with osteoclast-like giant cells. , 2009, Archives of pathology & laboratory medicine.

[2]  E. Musulen,et al.  Gastrointestinal stromal tumors , 2006, Abdominal Imaging.

[3]  C. Zeng,et al.  Clinical manifestations and prognostic factors in patients with gastrointestinal stromal tumors. , 2003, World journal of gastroenterology.

[4]  A. D. Van den Abbeele,et al.  Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Philippe Soriano,et al.  Roles of PDGF in animal development , 2003, Development.

[6]  M. Sobrinho-Simões,et al.  Aggressive mixed tumour, salivary gland type of the bone , 2003, Histopathology.

[7]  S. Hirota,et al.  Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. , 2003, Gastroenterology.

[8]  S. Hirota,et al.  Gastrointestinal stromal tumors (GIST): A model for molecule‐based diagnosis and treatment of solid tumors , 2003, Cancer science.

[9]  J. Greenson.  Gastrointestinal Stromal Tumors and Other Mesenchymal Lesions of the Gut , 2003, Modern Pathology.

[10]  D. Weaver,et al.  c-Kit expression in desmoid fibromatosis. Comparative immunohistochemical evaluation of two commercial antibodies. , 2003, American journal of clinical pathology.

[11]  C. Fletcher,et al.  Validating immunohistochemical staining for KIT (CD117). , 2003, American journal of clinical pathology.

[12]  Samuel Singer,et al.  PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors , 2003, Science.

[13]  V. Sondak,et al.  Response of extraabdominal desmoid tumors to therapy with imatinib mesylate , 2002, Cancer.

[14]  G. Demetri,et al.  Management of malignant gastrointestinal stromal tumours. , 2002, The Lancet. Oncology.

[15]  J. Fletcher,et al.  Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[17]  L. Sobin,et al.  Diagnosis of gastrointestinal stromal tumors: A consensus approach. , 2002, Human pathology.

[18]  M. Heinrich,et al.  KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. , 2002, The American journal of pathology.

[19]  J. Fletcher,et al.  Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. , 2002, Human pathology.

[20]  C. Fletcher,et al.  Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. , 2002, American journal of clinical pathology.

[21]  C. J. Chen,et al.  KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. , 2001, Cancer research.

[22]  Sigrid Stroobants,et al.  Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study , 2001, The Lancet.

[23]  D. George,et al.  Platelet-derived growth factor receptors: a therapeutic target in solid tumors. , 2001, Seminars in oncology.

[24]  J. Berman,et al.  Gastrointestinal stromal tumor workshop. , 2001, Human pathology.

[25]  T. Satou,et al.  Malignant gastrointestinal stromal tumor showing remarkable whorl formations. , 2001, Archives of pathology & laboratory medicine.

[26]  D. Tuveson,et al.  Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. , 2001, The New England journal of medicine.

[27]  M. Miettinen.  Are desmoid tumors kit positive? , 2001, The American journal of surgical pathology.

[28]  B. Druker,et al.  Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. , 2000, The Journal of pharmacology and experimental therapeutics.

[29]  L. Sobin,et al.  Immunohistochemical Spectrum of GISTs at Different Sites and Their Differential Diagnosis with a Reference to CD117 (KIT) , 2000, Modern Pathology.

[30]  C. Compton,et al.  Gastrointestinal stromal tumor versus intra-abdominal fibromatosis of the bowel wall: a clinically important differential diagnosis. , 2000, The American journal of surgical pathology.

[31]  J. Fletcher,et al.  KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. , 2000, The American journal of pathology.

[32]  C. Heldin,et al.  Signal transduction via platelet-derived growth factor receptors. , 1998, Biochimica et biophysica acta.

[33]  A. Kovatich,et al.  CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[34]  L. Kindblom,et al.  Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. , 1998, The American journal of pathology.

[35]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.

[36]  Philippe Soriano.  The PDGF alpha receptor is required for neural crest cell development and for normal patterning of the somites. , 1997, Development.

[37]  J. Goldblum.  CD34 positivity in fibrosarcomas which arise in dermatofibrosarcoma protuberans. , 1995, Archives of pathology & laboratory medicine.

[38]  C. Heldin,et al.  Expression of Platelet-Derived Growth Factor (PDGF) and PDGF α- and β-Receptors in the Peripheral Nervous System: An Analysis of Sciatic Nerve and Dorsal Root Ganglia , 1993 .

[39]  A. Ullrich,et al.  Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors , 1986, Nature.

[40]  Juthamas Sukbuntherng,et al.  In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  C. Heldin,et al.  Involvement of platelet-derived growth factor in disease: development of specific antagonists. , 2001, Advances in cancer research.

[42]  J. Lasota,et al.  Gastrointestinal stromal tumors – definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis , 2000, Virchows Archiv.

[43]  L. Sobin,et al.  Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. , 1999, The American journal of surgical pathology.

[44]  C. Heldin,et al.  Expression of platelet-derived growth factor (PDGF) and PDGF alpha- and beta-receptors in the peripheral nervous system: an analysis of sciatic nerve and dorsal root ganglia. , 1993, Developmental biology.